“Unmet Needs in hATTR Amyloidosis in Europe” explores challenges for patients living with a rare disease caused by a build-up of abnormal protein in different organs. Hereditary transthyretin (hATTR) amyloidosis can lead to debilitating cardiovascular, neurological, renal or other symptoms. Timely diagnosis and treatment can slow or even stop the progression of the disease. Yet gaps in access and unmet needs make that difficult for some patients.
As identified by amyloidosis stakeholder organisations from across Europe, five unmet needs in particular inhibit optimal care:
Facilitating better treatment outcomes and improved quality of life stands to benefit patients, their carers and families, and their communities. Achieving those outcomes, however, must begin with policymakers and advocates working hand in hand to address these significant and persistent unmet needs.